An Interesting Year for FDA Watchers -- What Should They Do Next About Rosiglitzone?

Hi, I'm Dr. Henry Black. I'm a Clinical Professor of Internal Medicine at the New York University School of Medicine, member of the Center for the Prevention of Cardiovascular Disease, and Immediate Past President of the American Society of Hypertension.

The summer of 2010 has been a very interesting season for US Food and Drug Administration (FDA) watchers. Avastin®, a cancer drug, recently lost its indication for breast cancer, and rosiglitazone (Avandia®) was the subject of a very long and exhaustive review by the agency and 33 people who evaluated the data.[1] [Correction: The FDA Oncologic Drug Advisory Committee recommended that Avastin’s indication for metastatic breast cancer should be revoked, but the FDA is still to make a final decision, which is due in mid-Sept.]

Full text at Medscape